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Abstract
Fabry's Disease is a rare genetic syndrome, with a classic X-linked alpha -galactosidase A deficiency
phenotype, responsible for glico-sphyngolypids metabolism impairment with clinical effects in
several organs and functions. We describe the anaesthesiologic implications of two patients with
Fabry disease who underwent a kidney transplantation from a deceased donor. We recommend
careful preoperative evaluation, including cardiac sonography study and spirometry for Fabry
disease patients, and according to our experience, we recommend advanced haemodynamic
monitoring during surgery. Careful airway examination should be further performed, with
particular attention to patient ventilability prediction and available alternative strategies for airway
management in case of difficulties. A nephroprotective strategy and a particular care to the
associated end-stage organ disease may significantly improve the long-term outcome of patients
with Fabry Disease.
Introduction
Fabry Disease (FD) is a rare genetic syndrome, with a clas-
sic X-linked alpha -galactosidase A (alpha -Gal A) defi-
ciency phenotype; it has an estimated incidence of
approximately 1 in 40,000 – 50,000 males, with recent
epidemiologic evidence of later-onset variants [1]. The
underlying enzymatic defect consists in lisosomial alpha
galactosidase deficit, responsible for glico-sphyngolypids
metabolism impairment resulting in the accumulation of
uncleaved glycosphingolipids in many human cell types,
with clinical effects in several organs and functions. The
enzymatic defect leads to progressive accumulation of gly-
cosphingolipids in vascular endothelial cells, renal cells
and cardiomyocytes. Classically, homozygous young
males are severely affected by Fabry disease, whose mani-
festations appear during early years of extra-uterine life.
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Proteinuria usually manifests before the fourth decade of
life and rapidly progresses to end-stage renal disease
requiring dialysis and kidney transplantation [1]. Kidney
transplantation is the best available method to restore a
normal renal function with an excellent long term graft
and patient survival, and it improves extrarenal clinical
symptoms of Fabry disease [2,3]. Patients with Fabry dis-
ease are at high surgical risk, due to impaired renal and
respiratory function, cerebrovascular and cardiovascular
disease, and intraoperative management may be challeng-
ing. However, very little is known about anaesthetic
implication in the management of patients with Fabry dis-
ease who underwent a kidney transplantation [4,5]
Case presentations
We herein describe two patients with Fabry disease who
underwent a deceased donor kidney transplantation, by
focusing on the anaesthesiologic implications for this rare
disease.
Case 1
42 year-old male patient, ASA III; positive anamnesis for
hypertension, left ventricular hypertrophy, incomplete
right bundle block, moderate mitralic and aortic insuffi-
ciency; end-stage kidney disease in dialysis for 5 years.
Diffuse angiokeratomas, especially in lower limbs and
inferior abdomen.
Case 2
53 years old male patient, ASA III; myocardial infarction 3
years before, no revascularization or angioplasty. Hyper-
tension, chronic obstructive lung disease with borderline
spirometry and end-stage renal disease in dialysis for 8
years. Diffuse angiokeratomas in lower limbs, abdomen
and thorax.
Anaesthesiological implications for both patients might
be relevant: however, despite the underlying Fabry dis-
ease, standard anaesthesiological protocol for kidney
transplantation was applied: propofol 1.5 mg*kg-1, cisat-
racurium 2 mg*kg-1  and fentanil 1.5 mcg*kg-1  were
administered for anaesthesia induction, while mainte-
nance was performed with sevoflurane 1–1.5 MAC and
fentanil/cisatracurium boluses on demand. Accordingly
to our protocol, fenoldopam continuous infusion was
performed up to 3rd postoperative day; one of two
patients received "nephroprotective" infusion at standard
0.1 mcg*kg-1 *min-1, while one patient received scalar
doses up to 0.8 mcg*kg-1 *min-1 to control unresponsive
hypertension. Cardio-haemodinamic management was
standard 3 leads EKG, invasive blood pressure (difficult
arterial cannulation in both cases) and in the second
patient it included non invasive cardiac output measure-
ment via PRAM® monitor (arterial waveform advanced
analysis). Careful haemodynamic monitoring was useful
for both intra-operative fluid management and to titrate
anti-hypertensive therapy. Both patients received intraop-
erative transdermal nitroglycerine during surgery.
Interestingly, one patient showed unexpected laryngo-
scopic and intubation difficulty, despite normal antropo-
metric predictive parameters. Ventilation was always
granted and intubation was achieved at third attempt
using McCoy blade and Frova Hollow introducer (Cook®
– Bloomington – USA).
In both patients awakening was uneventful after uncom-
plicated surgery; extubation was performed in operative
room and incentival spirometry was started immediately
the day after surgery. Analgesia was granted with intrave-
nous morphine.
In both cases renal function restored on day 2 and 3 post-
transplant, respectively, with no needs for dialysis. At a
follow up of 52 months and 13 months, respectively, both
recipients are alive, in treatment with algasidase beta
replacement therapy, and have an excellent renal func-
tion.
Discussion
Renal pathology is one of the hallmarks of FD and is the
most frequent cause of death, usually when patients are
aged 30–50 years. Polyuria due to concentration defects
can be among the first manifestations of kidney involve-
ment, and it is always accompanied or immediately fol-
lowed by rapid evolving proteinuria [1].
Global concentric ventricular hypertrophy, valvular
abnormalities and cardiac conduction disturbance are
common in affected males older than 30 years [6]. More-
over, disease of the airways appears to be significantly
worse in male patients and smokers[7].
In conclusion, preoperative assessment of FD should con-
centrate on end-stage organ damage to the hearth, brain,
lungs and kidneys. Patients with Fabry disease who are
undergoing a kidney transplantation need a careful preop-
erative evaluation of cardio-pulmonary functionality,
including echo-cardiography and spirometry, and an
advanced haemodynamic monitoring during surgery, to
prevent severe cardiovascular and respiratory impairment.
Our clinical reports demonstrated that a standard anaes-
thesiological protocol could be applied in these patients.
However, a special care should be addressed to the treat-
ment of concomitant pathologies, which may signifi-
cantly adverse the early postoperative outcome. A careful
airway examination should be further performed, with
particular attention to patient ventilability prediction and
available alternative strategies for airway management in
difficult cases. Finally, a nephroprotective strategy shouldPublish with BioMed Central    and   every 
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be applied to all recipients to improve the long term out-
come of transplanted patients with Fabry disease.
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